EUVIMEDEUVIMED entdecken
Crossref

Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer

Arnaud Dieudonné iD, Aya Terro, Arthur Dumouchel, Solène Perret, Adrien Pommier, Agathe Edet-Sanson, Pierre Vera, Frédéric Di Fiore, Laetitia Augusto, Pierre Decazes, David Tonnelet

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07823-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Arnaud Dieudonné und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France. arnaud.dieudonne@me.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Région Normandie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To assess the clinical value of single-time-point dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Fifty-nine patients with progressive mCRPC expressing PSMA and previously treated with androgen receptor pathway inhibitors and taxane-based chemotherapy were retrospectively analysed. SPECT/CT imaging was performed after the first (C1) and fourth (C4) [¹⁷⁷Lu]Lu-PSMA-617 infusions on 360°-CZT camera. Automated segmentation and dosimetry protocols were applied to quantify absorbed doses in bone marrow and lesions. Dose-effect relationships were assessed using blood counts, PSA responses (PSA50 criteria), and PET imaging. Statistical analyses included Spearman correlation, Wilcoxon signed-rank test, and logistic regression. RESULTS: Bone marrow absorbed dose (BMAD) at C1 was significantly correlated with red blood cells (RBC, ρ = -0.3) and haemoglobin (ρ = -0.26) decline. A higher BMAD was associated with greater declines in RBC count (median [IQR] 0.31 [0.33] Gy vs. 0.076 [0.19], p < 0.05) and haemoglobin (0.29 [0.41] vs. 0.092 [0.20], p = 0.056). A moderate negative correlation was found between PSA variation and total metastatic tumour absorbed (TMTAD) dose at C1 (ρ = -0.35) and from C1 to C4 (ρ = -0.35). Response modelling (based on PSA50) estimated 50% and 80% probabilities of response at 8.8 Gy and 18.1 Gy for TMTAD(C1) and at 11.3 Gy and 31.7 Gy for TMTAD(C1-C4). CONCLUSION: Single-time-point dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 therapy in mCRPC is clinically relevant, demonstrating dose-dependent haematological decline and therapeutic response. This approach has the potential to facilitate more personalised and accessible radioligand therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingLutetiumHumansMaleRadiometryRadioisotopesAgedNeoplasm MetastasisRetrospective StudiesAutomationMiddle AgedRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyTime FactorsAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMAClinical dosimetryRadioligand therapyRadiopharmaceuticalSingle time

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumRadioisotopesPSMA-617Lutetium-177Radiopharmaceuticalslutetium (177Lu) vipivotide tetraxetanProstate-Specific Antigen

Autor:innen und Institutionen

  • Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France. arnaud.dieudonne@me.com.
  • AIMS-Quantif, University of Rouen, Rouen, France. arnaud.dieudonne@me.com.
  • AIMS-Quantif, University of Rouen, Rouen, France.
  • Nuclear Medicine Department, Henri Becquerel Cancer Center, Rouen, France.
  • Department of Digestive and Urological Oncology, Rouen University Hospital, Rouen, France.

ORCID-Profile: Arnaud Dieudonné

Förderung

  • Région Normandie

Zitieren

APA

Dieudonné, A., Terro, A., Dumouchel, A., Perret, S., Pommier, A., Edet-Sanson, A., Vera, P., Di Fiore, F., Augusto, L., Decazes, P., & Tonnelet, D. (2026). Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07823-4

Vancouver

Dieudonné A, Terro A, Dumouchel A, Perret S, Pommier A, Edet-Sanson A, et al. Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07823-4

BibTeX
@article{Dieudonn2026,
  author = {Dieudonné, Arnaud and Terro, Aya and Dumouchel, Arthur and Perret, Solène and Pommier, Adrien and Edet-Sanson, Agathe and Vera, Pierre and Di Fiore, Frédéric and Augusto, Laetitia and Decazes, Pierre and Tonnelet, David},
  title = {Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07823-4}
}
Kostenlos starten →